Janssen Presented Results of RSV Vaccine in P-IIb CYPRESS Study for Lower Respiratory Tract Disease Due to Respiratory Syncytial Virus at IDWeek 2021
Janssen Enters into a License and Collaboration Agreement with F-star to Develop and Commercialize Multiple Bispecific Antibody Therapeutics
Shots:
- The P-IIb CYPRESS study evaluates the efficacy & safety of RSV vaccine vs PBO in a ratio (1:1) in 5782 patients aged ≥65 with LRTD caused by RSV
- The study met its 1EPs & 2EPs i.e., 80% efficacy against RSV-associated LRTD & 70% against any symptomatic RSV-associated ARI. The vaccine showed robust humoral & cellular immune responses & a substantial increase in RSV neutralizing Abs 14 days after vaccination & was generally well-tolerated
- The company also initiates the P-III EVERGREEN study of RSV vaccine vs PBO in ~23000 adults aged ≥60yrs. for the same indication across North America, EU, Asia & Southern Hemisphere based on the results from the P-IIb CYPRESS study
Click here to read full press release/ article | Ref: J&J | Image: Clinical Trials Arena